Search Results

1.Management of Colorectal Cancer Liver Metastasis.

Journal of the Korean Society of Coloproctology 2000;16(1):47-56

The liver is the predominant metastatic site of colorectal cancer. When the patients general condition, the absence of extrahepatic metastases, number and locations of hepatic lesions permit, hepatic resection may be curative and should be considered standard therapy. Regional approaches, such as cryotherapy, alcohol injection, radiation therapy, interstitial laser therapy, and chemoembolization even that may bring about effective palliation suggest experimental approaches to the treatment of hepatic metastases. Regional infusion of chemotherapeutic agent via hepatic artery has shown a great tumor response, but further studies are needed for evaluation of precise benefit of this approach. Manipulation of the gene level was recently possible and addressed for the treatment of unresectable hepatic metastases, but still many problems to overcome are remained for the effective delivery and selective expression of the therapeutic gene or gene product to the target cells. Thus, new approaches to the colorectal cancer liver metastases are clearly warranted.
Colorectal Neoplasms* ; Cryotherapy ; Hepatic Artery ; Humans ; Laser Therapy ; Liver* ; Neoplasm Metastasis*

2.The curative fistulectomy including the repair of the anal sphincter muscle in the anal fistula.

Yang LEE ; Jin Cheon KIM ; Dae Yong HWANG

Journal of the Korean Society of Coloproctology 1992;8(3):247-252

PURPOSE:Ghrelin is an endogenous ligand of the growth hormone secretagogue receptor, and stomach is the major site of ghrelin secretion. The purpose of this study is to compare the serum ghrelin concentrations between patients with type 2 diabetes mellitus (DM) and normal adults. We studied also whether serum ghrelin levels in the patients with type 2 DM are correlated with body mass index (BMI), serum insulin, lipid profiles, and creatinine levels. METHODS:Forty patients with type 2 DM and forty normal adults were included in this study. We measured heights and weights of the subjects and calculated their BMIs. Blood samples were obtained to measure the ghrelin concentration and their sera were stored at -20degreeC until used. In all subjects, serum ghrelin levels were measured using the commercially available Ghrelin(human) EIA kit. RESULTS:No differences of mean values were detected between the control group and the type 2 diabetic group for age, body weight, BMI, and the levels of serum total cholesterol, triglyceride, HDL cholesterol, and creatinine. But ghrelin level of the type 2 diabetic group (71.1+/-30.5 ng/L) was significantly lower than the control group (139.7+/-36.9 ng/L). In the control group, the ghrelin level showed positive correlation with HDL cholesterol (Pearson's correlation coefficient=0.37, P<0.05). In the diabetic group, the ghrelin level showed weakly positive correlation with insulin concentration. However, there was no significant relationship between serum ghrelin and various parameters in the diabetic patients group. CONCLUSION: In this study, ghrelin concentration in type 2 diabetic patients was lower than that in the control group. In the control group, serum ghrelin concentrations were positively correlated with HDL cholesterol. In the type 2 diabetic group, there was no significant correlation between insulin and ghrelin concentrations.
Adult ; Body Mass Index ; Body Weight ; Cholesterol ; Cholesterol, HDL ; Creatinine ; Diabetes Mellitus ; Diabetes Mellitus, Type 2* ; Ghrelin* ; Humans ; Insulin ; Receptors, Ghrelin ; Stomach ; Triglycerides ; Weights and Measures